Effect of neonatal surfactant therapy on lung function at school age in children born very preterm

Pediatric Pulmonology

Volumn 25, Issue 3, 1998, Pages 182-190

  Pelkonen, Anna S ^a   Hakulinen, A L ^a   Turpeinen, M ^a   Hallman, M ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

Lung function; Neonatal respiratory distress syndrome; Prematurity; Randomized controlled trial; Surfactant therapy

Indexed keywords

LUNG SURFACTANT;

ARTICLE; BRONCHUS OBSTRUCTION; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; MALE; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; SCHOOL CHILD; SPIROMETRY; TREATMENT OUTCOME;

ADRENERGIC BETA-AGONISTS; AIRWAY OBSTRUCTION; BRONCHIAL DISEASES; CHILD; CIRCADIAN RHYTHM; FEMALE; FOLLOW-UP STUDIES; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INTUBATION, INTRATRACHEAL; LUNG; MALE; OXYGEN INHALATION THERAPY; PEAK EXPIRATORY FLOW RATE; PLACEBOS; PULMONARY SURFACTANTS; REGRESSION ANALYSIS; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, NEWBORN; SPIROMETRY; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 0031977395     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0496(199803)25:3<182::AID-PPUL8>3.0.CO;2-O     Document Type: Article

References (41)

1. Soll RF, McQueen MC, Respiratory distress syndrome. In: Sinclair JC, Bracken MB, eds. Effective Care of the Newborn Infant. Oxford: Oxford University Press, 1992:325-358.
2. Horbar JD, Wright EC, Onstad L. Decreasing mortality associated with the introduction of surfactant therapy: An observational study of neonates weighing 601 to 1300 grams at birth. Pediatrics. 1993; 92:191-196.
3. Schwartz RM, Luby AM, Scanlon JW, Kellogg RJ. Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500 to 1500 g. N Engl J Med. 1994; 330:1476-1480.
4. Raju TNK, Langenberg P. Pulmonary hemorrhage and exogenous surfactant therapy: A metaanalysis. J Pediatr. 1993; 123:603-610.
5. Morley CJ, Greenough A. Respiratory compliance in premature babies treated with artificial surfactant (ALEC). Arch Dis Child. 1991; 66:467-471.
6. Couser RJ, Ferrara TB, Ebert J, Hoekstra RE, Fangman JJ. Effect of exogenous surfactant therapy on dynamic compliance during mechanical breathing in preterm infants with hyaline membrane disease. J Pediatr. 1990; 116:119-124.
7. Bhutani VK, Abbasi S, Long WA, Gerdes JS. Pulmonary mechanics and energetics in preterm infants who had respiratory distress syndrome treated with synthetic surfactant. J Pediatr. 1992; 120: 18-24.
8. Yuksel B, Greenough A, Gamsu HR. Respiratory function at follow-up after neonatal surfactant replacement therapy. Respir Med. 1993; 87:217-221.
9. Abbasi S, Bhutani VK, Gerdes JS. Long-term pulmonary consequences of respiratory distress syndrome in preterm infants treated with exogenous surfactant. J Pediatr. 1993; 122:446-452.
10. Hallman M, Merritt TA, Järvenpää A-L, Boynton B, Mannino F, Gluck L, Moore T, Edwars D. Exogenous human surfactant for treatment of severe respiratory distress syndrome: A randomized prospective clinical trial. J Pediatr. 1985; 106:963-969.
11. Merritt TA, Hallman M, Bloom BT, Berry C, Benirschke K, Sahn D, Key T, Edwards D, Järvenpää A-L, Pohjavuori M, Kankaanpää K, Kunnas M, Paatero H, Rapola J, Jääskeläinen J. Prophylactic treatment of very premature infants with human surfactant. N Engl J Med. 1986; 315:785-790.
12. Merritt TA, Hallman M, Berry C, Pohjavuori M, Edwards DK, Jääskeläinen J, Grafe MR, Vaucher Y, Wozniak P, Heldt G, Rapola J. Randomized, placebo-controlled trial of human surfactant given at birth versus rescue administration in very low birth weight infants with lung immaturity. J Pediatr. 1991; 118:581-594.
13. Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: Prediction from oxygen requirement in the neonatal period. Pediatrics. 1988; 82:527-532.
14. American Thoracic Society. Standardization of spirometry - 1987 update. Am Rev Respir Dis. 1987; 136:1285-1298.
15. Polgar G, Promadhat V. Pulmonary function testing in children: Technics and standards. Philadelphia: WB Saunders, 1971:42-212.
16. Pedersen S, Hansen OR, Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child. 1990; 65: 308-319.
17. Hetzel MR, Clark TJH. Comparison of normal and asthmatic circadian rhythms in peak expiratory flow rate. Thorax. 1980; 35: 732-738.
18. Enright PL, Lebowitz MD, Cockroft DW. Physiologic measures: Pulmonary function tests. Am J Respir Crit Care Med. 1994; 149:9-18.
19. Hallman M, Merritt TA, Akino T, Bry K. Surfactant protein A, phosphatidylcholine, and surfactant inhibitors in epithelial lining fluid. Correlation with surface activity, severity of respiratory distress, syndrome and outcome in small premature infants. Am Rev Respir Dis. 1991; 144:1376-1384.
20. American Thoracic Society. Lung function testing: Selection of reference values and interpretative strategies. Am Rev Respir Dis. 1991; 144:1202-1218.
21. Kendig JW, Notter RH, Cox C, Reubens LJ, Davis JM, Maniscalco WM, Sinkin RA, Bartoletti A, Dweck HS, Horgan MJ, Risemberg H, Phelps DL, Shapiro DL. A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks' gestation. N Engl J Med. 1991; 324:865-871.
22. Kattwinkel J, Bloom BT, Delmore P, Davis CL, Farrell E, Friss H, Jung AL, King K, Mueller D. Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks' gestation. Pediatrics. 1993; 92:90-98.
23. The OSIRIS Collaborative Group. Early versus delayed neonatal administration of a synthetic surfactant: The judgment of OSIRIS. Lancet. 1992; 340:1363-1369.
24. Halliday HL. Surfactant replacement therapy. Pediatr Pulmonol. 1995; Suppl 11:96-97.
25. Cooke R. The current use of exogenous surfactants in the newborn. Br J Obstet Gynaecol. 1995; 102:679-681.
26. Davis JM, Veness-Meehan K, Notter RH, Bhutani VK, Kendig JW, Shapiro DL. Changes in pulmonary mechanics after the administration of surfactant to infants with respiratory distress syndrome. N Engl J Med. 1988; 319:476-479.
27. Milner AD. How does exogenous surfactant work? Arch Dis Child. 1993; 68:253-254.
28. Goldman SL, Bosque E, McCann E, Lewis K. Pulmonary mechanics in premature infants one month after treatment with synthetic surfactant. J Pediatr. 1992; 120:25-28.
29. Walti H, Boule M, Moriette G, Relier J-P. Pulmonary functional outcome at one year of age in infants treated with natural porcine surfactant at birth. Biol Neonate. 1992; 61(suppl 1):48-53.
30. Couser RJ, Ferrara TB, Wheeler W, McNamara J, Falde B, Johnson K, Hoekstra RE. Pulmonary follow-up 2.5 years after a randomized, controlled, multiple dose bovine surfactant study of preterm newborn infants. Pediatr Pulmonol. 1993; 15:163-167.
31. Kramer BM, Sinkin RA, Merzbach JL, Myers GJ, Brooks JG, Palumbo DR, Cox C, Kendig JW, Phelps DL. Improved pulmonary outcome at school age with prophylactic surfactant administration. Pediatr Res. 1995; 37:263A.
32. Berner M, Gappa M, Hohenschild S, Dammann C, Bartmann P. Lung function at school-age in children participating in a randomized surfactant trial (Alveofact®) for treatment of RDS. Pediatr Res. 1996; 39:326A.
33. Vaucher YE, Harker L, Merritt TA, Hallman M, Bejar KGR, Heldt GP, Edwards D, Pohjavuori M. Outcome at twelve months of adjusted age in very low birth weight infants with lung immaturity: A randomized, placebo-controlled trial of human surfactant. J Pediatr. 1993; 122:126-132.
34. Hallman M, Merritt TA, Bry K, Berry C. Association between neonatal care practices and efficacy of exogenous human surfactant: results of a bicenter randomized trial. Pediatrics. 1993; 91: 552-560.
35. Robertson B. Animal models of neonatal surfactant dysfunction. In: Robertson B, Van Golde LMG, Batenburg JJ, eds. Pulmonary Surfactant: From Molecular Biology to Clinical Practice. Amsterdam: Elsevier Science Publishers, 1992:459-484.
36. Fracica PJ, Caminiti SP, Piantadosi CA, Duhaylongsod FG, Crapo JD, Young SL. Natural surfactant and hyperoxic lung injury in primates II. Morphometric analyses. J Appl Physiol. 1994; 76: 1002-1010.
37. Jackson RM. Molecular, pharmacologic, and clinical aspects of oxygen-induced lung injury. Clin Chest Med. 1990; 11:73-86.
38. Rona RJ, Gulliford MC, Chinn S. Effects of prematurity and intrauterine growth on respiratory health and lung function in childhood. BMJ. 1993; 306:817-820.
39. Knoppert DC, Mackanjee HR. Current strategies in the management of bronchopulmonary dysplasia: The role of corticosteroids. Neonatal Network. 1994; 13:53-60.
40. Kari MA, Hallman M, Eronen M, Teramo K, Virtanen M, Koivisto M, Ikonen RS. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: A randomized placebo-controlled multicenter study. Pediatrics. 1994; 93:730-736.
41. Vijayakumar E, Soll RF, Bracken MB, Sinclair JC. Early postnatal corticosteroids for the prevention of chronic lung disease (CLD): Meta-analysis of clinical trials. Pediatr Res. 1995; 37:276A.